Navigation Links
Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
Date:5/31/2013

ubtypes for colorectal and colon cancer," Macdonald added. "Agendia has a rich history of presenting innovative and ground-breaking research that benefits oncologists and their cancer patients."

A more complete list of presentation abstracts can be found on ASCO's website at www.asco.org.

About Agendia:
Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products. Agendia's breast cancer Symphony suite was developed by analyzing the complete human genome, ensuring 100% definitive results for cancer patients. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The Company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.  For more information, please visit www.agendia.com.


'/>"/>
SOURCE Agendia
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Convergence Pharmaceuticals Announces Successful Interim Data from Ground-Breaking Phase II Trigeminal Neuralgia Study
2. Lilly Statement on Indiana Biosciences Research Institute
3. Breast Cancer Imaging Market: US, EU, South America Analysis & Forecast Research Reports
4. New Research Shows Continuing Medical Education Saves Healthcare Costs
5. Alzheimer Market: Drugs, Therapeutics & Diagnostics Research Reports
6. Cempra Awarded $58 Million Contract to Develop Antibiotic for Pediatric Use and Biodefense by Biomedical Advanced Research and Development Authority (BARDA)
7. International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma
8. Clinical Team Researching the Impact of the EarlySense System Wins Best Novel Idea Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference
9. Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis
10. Research-based Pharmaceutical Industry Launches Do You Mind? Campaign to Fight Mental and Neurological Disorders
11. Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... The nuclear imaging market is estimated to ... of 12.08%. Nuclear medicine is the use of radioisotopes ... of Nuclear imaging used commonly are PET and SPECT. ... nuclear medicine applications like nuclear cardiology procedures. However, the ... shortage of molybdenum-99 isotope which is in turn will ...
(Date:6/1/2015)... , June 1, 2015 ... weight over large area and improve the quality life ... ulcer. These devices play a significant role in inhibiting ... reduce the need to turn or rotate an immobile ... include mattress, mattresses overlay, and specialty beds. These devices ...
(Date:6/1/2015)... MECHANICSBURG, Pa. , June 1, 2015 ... announced that MJ Acquisition Corporation, a joint venture that ... Stowe XII, L.P., has completed its previously announced acquisition ... in the new joint venture. About ... leading operator of specialty hospitals and outpatient rehabilitation clinics ...
Breaking Medicine Technology:North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 2North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 3Global Pressure Relief Devices Market 2015-2019 2Global Pressure Relief Devices Market 2015-2019 3Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 2Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 3
... /PRNewswire-FirstCall/ -- La Jolla,Pharmaceutical Company today announced updated ... of Riquent(R) (abetimus,sodium), its drug candidate for systemic ... the previous,conclusion that there is a definitive and ... and 900 mg doses of Riquent compared,with placebo ...
... Calando,Pharmaceuticals, a leading siRNA therapeutics company and ... announced the publication in the Proceedings of ... journal of the,NAS, of the first non-human ... Calando's lead siRNA therapeutic candidate that is ...
Cached Medicine Technology:La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 2Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 3Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 4Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 5
(Date:6/2/2015)... June 02, 2015 Each year, Cosmetic ... Choice Beauty Awards. This year, the organization’s members – ... winner of the QVC® Beauty Quest Award at the ... Micro Emulsion (ME) Technology and 2-in-1 approach to skincare ... noting the brand’s loyal consumer and professional fan bases, ...
(Date:6/2/2015)... Join us for a new event in Westwood, New Jersey—the ... , who overcame her brain aneurysm during the summer of ... awareness and funds for brain aneurysm research. , Rhonda ... will be one less case of someone suffering from a ... the 1st Anniversary Awareness Walk in Honor of Rhonda ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Specialty ... audit, compliance and risk solutions , and Radar ... risk management effectiveness gap-improvement program. , All organizations ... uncertainty on objectives. Organizations not only assess and ... capabilities to do this (risk managing) thereby embedding ...
(Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... Lynn Lester as a 2015-2016 inductee into ... recognized with this prestigious distinction for leadership in business. ... professional women, boasting more than 700,000 members and over ... Lynn Lester with this prestigious award,” said NAPW President ...
(Date:6/1/2015)... 02, 2015 The National Association ... as a 2015-2016 inductee into its VIP Professional ... this prestigious distinction for leadership in safety, environment, health ... organization exclusively for professional women, boasting more than 700,000 ... pleased to present Lourinda with this important honor,” said ...
Breaking Medicine News(10 mins):Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2Health News:New Awareness Raising Event in Westwood, NJ to Benefit Renowned Brain Aneurysm Foundation 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2
... interdisciplinary team of researchers at Brigham and Women,s ... Sciences and Technology has demonstrated a better way to ... engineered nanoparticles that can inhibit a signaling pathway and ... area. Details of their work appear on April 20, ...
... Lincare Holdings Inc. (Nasdaq: LNCR ), a ... to patients in the home, today announced financial results for ... March 31, 2009, net revenues were $371.7 million, compared with ... 2008. Net income for the quarter ended March 31, ...
... April 20 Amgen (Nasdaq: AMGN ) today ... results on Thursday, April 23, 2009 after the close of ... conference call with the investment community at 2 p.m. Pacific ... Kevin Sharer, chairman and chief executive officer, and other members ...
... not have same impact, study finds , , MONDAY, April ... beverages can have a negative effect on the body,s ... increasing the risk of heart attack and stroke, a ... have that kind of impact, the study found. , ...
... SYK ) reported operating results for the quarter ended March ... , Net sales increased ... $1,601 million , Orthopaedic Implants ... reported) , MedSurg Equipment sales ...
... Environmental or therapeutic contact also led to poorer outcomes, ... Thyroid cancer patients who,ve previously been exposed to radiation ... patients, a new study finds. , Researchers at Mount ... who,d been exposed to radiation -- for example, in ...
Cached Medicine News:Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 2Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 3Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 4Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 2Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 3Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 4Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 5Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 6Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 7Health News:Amgen Announces Webcast of 2009 First Quarter Financial Results 2Health News:Stryker Operating Results for Quarter Ended March 31, 2009 2Health News:Stryker Operating Results for Quarter Ended March 31, 2009 3Health News:Stryker Operating Results for Quarter Ended March 31, 2009 4Health News:Stryker Operating Results for Quarter Ended March 31, 2009 5Health News:Stryker Operating Results for Quarter Ended March 31, 2009 6Health News:Stryker Operating Results for Quarter Ended March 31, 2009 7Health News:Stryker Operating Results for Quarter Ended March 31, 2009 8Health News:Radiation Exposure Linked to Aggressive Thyroid Cancers 2
... The Monarc Subfascial Hammock™ is ... female patients suffering from stress urinary ... by supporting the urethra during abdominal ... or laughing. Monarc's outside-to-in transobturator approach ...
... innovative architecture of the Uretex® ... and integrity for tension-free sling ... anchors securely to surrounding tissue ... alternate fixation devices, minimizing risk ...
Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support...
NephroMax High Pressure Nephrostomy Balloon Catheter allows one-step, atraumatic dilatation of the nephrostomy tract....
Medicine Products: